

Ocrevus™ (ocrelizumab)



When requesting Ocrevus (ocrelizumab), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Ocrevus is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis (MS).

Coverage Guidelines

The individual meets **all** of the following criteria for approval:

- 1) Has either relapsing form of multiple sclerosis (examples include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) or primary progressive multiple sclerosis; AND
- 2) Is 18 years of age or older; AND
- 3) Ocrevus is prescribed by or in consultation with a physician who specializes in the treatment of multiple sclerosis and/or a neurologist.

Approval duration (initial and renewal): 12 months

Recommended Dosing

The initial dose is 300mg IV, followed 2 weeks later by a second 300mg IV infusion; OR Maintenance doses are 600mg by IV infusion once every 6 months.

References

1. Ocrevus® injection for intravenous infusion [prescribing information]. San Francisco, CA: Genentech, Inc (a Member of the Roche Group); December 2020.
2. A Consensus Paper by the Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis. Updated September 2019. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf. Accessed on November 6, 2020.
3. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014;83:278-286.
4. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018;17(2):162-173.